Yervoy

ASCO Lung Cancer Roundtable - NSCLC Trial Updates: Checkmate 227 Opdivo Yervoy Combination Today

Dr. Postow on Nivolumab Combined With Ipilimumab in Melanoma

Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma

Ipilimumab/Nivolumab in First-Line mRCC

2 Drugs Making Strides in Oncology: Yervoy & Lenvima #Monthlylapinhealth Newsletter reel

Nivolumab with ipilimumab for mRCC

Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRC

Dr. Atkinson on When to Use Nivolumab Monotherapy Versus Nivolumab/Ipilimumab Combination

Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma

Metastatic RCC: Using Frontline Ipilimumab/Nivolumab

Optimizing the Use of Ipilimumab/Nivolumab in mRCC

Dr. Chiang Discusses Ipilimumab Plus Nivolumab in Small Cell Lung Cancer

Nivolumab vs ipilimumab for high risk melanoma patients

Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma

Adjuvant therapy with nivolumab combined with ipilimumab vs nivolumab alone in patients with res...

Dr. Ott Discusses Ipilimumab and Nivolumab in Melanoma

Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC

PRIME-HCC: ipilimumab and nivolumab in liver cancer

İpilimumab İmmunoterapi Prof Dr Başak Oyan Uluç

COSMIC-313: cabozantinib with nivolumab and ipilimumab in untreated aRCC

Opdivo + Yervoy Commercial (2024-2025)

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma